Norovirus
≈ 8 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Norovirus, also known as Norwalk virus, is the most common cause of gastroenteritis. The infection, sometimes referred to as the winter vomiting disease, is characterized by non-bloody diarrhea, vomiting, and stomach pain. Fever or headaches may also occur. Symptoms usually develop 24 hours after being exposed, and recovery typically occurs within one to three days. Complications are uncommon, but may include dehydration, especially in the young, the old, and those with other health problems. The virus is usually spread by the fecal–oral route. This may be through contaminated food or water or person-to-person contact. It may also spread via contaminated surfaces or through air from the vomit of an infected person. Risk factors include unsanitary food preparation and sharing close quarters. Diagnosis is generally based on symptoms. Confirmatory testing is not usually available but may be performed by public health agencies during outbreaks. Prevention involves proper hand washing and disinfection of contaminated surfaces. There is no vaccine or specific treatment for norovirus. Management involves supportive care such as drinking sufficient fluids or intravenous fluids. Oral rehydration solutions are the preferred fluids to drink, although other drinks without caffeine or alcohol can help.…
Norovirus, also known as Norwalk virus, is the most common cause of gastroenteritis. The infection, sometimes referred to as the winter vomiting disease, is characterized by non-bloody diarrhea, vomiting, and stomach pain. Fever or headaches may also occur. Symptoms usually develop 24 hours after being exposed, and recovery typically occurs within one to three days. Complications are uncommon, but may include dehydration, especially in the young, the old, and those with other health problems. The virus is usually spread by the fecal–oral route. This may be through contaminated food or water or person-to-person contact. It may also spread via contaminated surfaces or through air from the vomit of an infected person. Risk factors include unsanitary food preparation and sharing close quarters. Diagnosis is generally based on symptoms. Confirmatory testing is not usually available but may be performed by public health agencies during outbreaks. Prevention involves proper hand washing and disinfection of contaminated surfaces. There is no vaccine or specific treatment for norovirus. Management involves supportive care such as drinking sufficient fluids or intravenous fluids. Oral rehydration solutions are the preferred fluids to drink, although other drinks without caffeine or alcohol can help. Hand sanitizers based on alcohols tend to be ineffective against noroviruses due to their being non-enveloped, although some virus genotypes are more susceptible. Norovirus results in about 685 million cases of disease and 200,000 deaths globally a year. It is common both in the developed and developing world. Those under the age of five are most often affected, and in this group it results in about 50,000 deaths in the developing world. Norovirus infections occur more commonly during winter months. It often occurs in outbreaks, especially among those living in close quarters. In the United States, it is the cause of about half of all foodborne disease outbreaks. The virus is named after the city of Norwalk, Ohio, where an outbreak occurred in 1968.
Signs and symptoms
Norovirus infection is characterized by nausea, vomiting, watery diarrhea, abdominal pain, and in some cases, loss of taste. A person usually develops symptoms of gastroenteritis 24 hours after being exposed to norovirus. General lethargy, weakness, muscle aches, headaches, and low-grade fevers may occur. The disease is usually self-limiting, and severe illness is rare. Although having norovirus can be unpleasant, it is not usually dangerous, and most who contract it make a full recovery within two to three days. Norovirus can establish a long-term infection in people who are immunocompromised, such as those with common variable immunodeficiency or with a suppressed immune system after organ transplantation. These infections can be with or without symptoms. In severe cases, persistent infections can lead to norovirus‐associated enteropathy, intestinal villous atrophy, and malabsorption. Viruses in Norovirus are non-enveloped, with icosahedral geometries. Capsid diameters vary widely, from 23 to 40 nm in diameter. The larger capsids (38–40 nm) exhibit T=3 symmetry and are composed of 180 VP1 proteins. Small capsids (23 nm) show T=1 symmetry, and are composed of 60 VP1 proteins. The virus particles demonstrate an amorphous surface structure when visualized using electron microscopy.
Genome
Noroviruses contain a linear, non-segmented, positive-sense RNA genome of approximately 7.5 kilobases, encoding a large polyprotein which is cleaved into six smaller non-structural proteins (NS1/2 to NS7) by the viral 3C-like protease (NS6), a major structural protein (VP1) of about 58~60 kDa and a minor capsid protein (VP2). The most variable region of the viral capsid is the P2 domain, which contains antigen-presenting sites and carbohydrate-receptor binding regions.
Evolution
Groups 1, 2, 3, and 4 last shared a common ancestor in AD 867. The group 2 and group 4 viruses last shared a common ancestor in approximately AD 1443 (95% highest posterior density AD 1336–1542). Several estimates of the evolution rate have been made, varying from 8.98 × 10 −3 to 2.03 × 10 −3 substitutions per site per year. The estimated mutation rate (1.21 to 1.41 substitutions per site per year) in this virus is high even compared with other RNA viruses. In addition, a recombination hotspot exists at the ORF1-ORF2 (VP1) junction.
Replication cycle
Viral replication is cytoplasmic. Entry into the host cell is achieved by attachment to host receptors, which mediates endocytosis. Positive-stranded RNA virus transcription is the method of replication. Translation takes place by leaky scanning and RNA termination-reinitiation. Humans and other mammals serve as the natural host. Transmission routes are fecal-oral and contamination.
Hand washing and disinfectants
Hand washing with soap and water is an effective method for reducing the transmission of norovirus pathogens. Alcohol rubs (≥62% isopropyl alcohol) may be used as an adjunct, but are less effective than hand-washing, as norovirus lacks a lipid viral envelope. Hand sanitizers based on alcohols tend to be ineffective against noroviruses due to their being non-enveloped, although some virus genotypes were found in in vitro tests with ethanol and isopropyl alcohol to be more susceptible. Alcohol susceptibility patterns between different norovirus genotypes were found to vary widely, and virolysis data for a single strain or genotype were not representative for all noroviruses. Another study found that alcohol in combination with acid (1% citric acid, e.g. from 15% concentrated lemon juice) produced an effective disinfectant of noroviruses. Surfaces where norovirus particles may be present can be sanitised with a solution of 1.5% to 7.5% of household bleach in water, or other disinfectants effective against norovirus.
Healthcare facilities
In healthcare environments, the prevention of nosocomial infections involves routine and terminal cleaning. Nonflammable alcohol vapor in CO 2 systems is used in health care environments where medical electronics would be adversely affected by aerosolized chlorine or other caustic compounds. In 2011, the CDC published a clinical practice guideline addressing strategies for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. Based on a systematic review of published scientific studies, the guideline presents 51 specific evidence-based recommendations, which were organized into 12 categories: 1) patient cohorting and isolation precautions, 2) hand hygiene, 3) patient transfer and ward closure, 4) food handlers in healthcare, 5) diagnostics, 6) personal protective equipment, 7) environmental cleaning, 8) staff leave and policy, 9) visitors, 10) education, 11) active case-finding, and 12) communication and notification. The guideline also identifies eight high-priority recommendations and suggests several areas in need of future research.
Vaccine trials
LigoCyte announced in 2007 that it was working on a vaccine and had started phase 1 trials. The company has since been taken over by Takeda Pharmaceutical Company. , a bivalent (NoV GI.1/GII.4) intramuscular vaccine had completed phase 1 trials. In 2020 the phase 2b trials were finished. The vaccine relies on using a virus-like particle that is made of the norovirus capsid proteins to mimic the external structure of the virus. Since there is no RNA in this particle, it is incapable of reproducing and cannot cause an infection. Virus Pathogen Database and Analysis Resource (ViPR): Caliciviridae 3D structure of Norovirus from the EM Data Bank at the European Bioinformatics Institute UK Viralzone: Norovirus ICTV Report: Caliciviridae
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372313732 under CC BY-SA 4.0; modifications have been made.